Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: GU tumours, prostate

1359MO - Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE

Date

11 Sep 2022

Session

Mini Oral session: GU tumours, prostate

Topics

Clinical Research;  Radiological Imaging;  Therapy

Tumour Site

Prostate Cancer

Presenters

Áine Haran

Citation

Annals of Oncology (2022) 33 (suppl_7): S616-S652. 10.1016/annonc/annonc1070

Authors

Á.M. Haran1, Y. Jain2, T. Hambrock2, L.R. Murphy3, A. Cook4, L.C. Brown3, A.P. Hoyle5, A. Sachdeva6, S.A. Ali1, C.L. Amos3, M.R. Sydes3, G. Attard7, M.K. Parmar3, N.D. James8, N.W. Clarke9

Author affiliations

  • 1 Genito-urinary Cancer Research Group, The University of Manchester, M20 4BX - Manchester/GB
  • 2 Department Of Radiology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 3 University College London (ucl), Medical Research Council Clinical Trials Unit (MRC CTU), WC1V 6LJ - London/GB
  • 4 University College London (ucl), Medical Research Council Clinical Trials Unit (MRC CTU), WC1 6LJ - London/GB
  • 5 Department Of Urology, The Christie and Salford Royal NHS Foundation Trusts, M20 4BX - Manchester/GB
  • 6 Department Of Surgery, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 7 Research Department Of Oncology, UCL Cancer Institute - UCL, WC1 E6BT - London/GB
  • 8 Prostate And Bladder Cancer Research Department, ICR - Institute of Cancer Research, SW7 3RP - London/GB
  • 9 Department Of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester/GB
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1359MO

Background

Better selection of patients (pts) for addition of docetaxel in mHSPC is required. Increased disease burden correlates with worse outcomes but nodal metastases have not been considered in metastatic volume definitions in mHSPC.

Methods

Overall survival (OS) was compared in subgroups of mHSPC pts (node +/- bone and bone-only), randomized 2:1 ADT +/- docetaxel or 1:1 ADT +/- AAP. Nodal burden was dichotomized into low (<5 nodes) and high (≥5 nodes) burden. Cox models were stratified by time period and adjusted for N stage, age (<70, ≥70), WHO PS, NSAID/aspirin use, radiotherapy (RT), bone metastases and CHAARTED low or high volume.

Results

1086 pts from ADT +/- docetaxel and 990 pts from ADT +/- AAP were studied. CT/MRI scans for 373 ADT +/- docetaxel and 602 ADT +/- AAP pts were also centralized and reviewed for nodal metastases. Significant OS benefit was demonstrated with ADT + AAP in both nodal +/- bone and bone-only metastases groups. Pts with bone-only metastases treated with ADT + docetaxel had a similar survival benefit. Notably, survival benefit was reduced for ADT + docetaxel in the nodal +/- bone metastases group. This difference was statistically significant by test for interaction (interaction HR 1.43, p=0.046). Higher nodal burden had significantly worse outcomes in both control arms and the research arm of ADT +/- AAP. Table: 1359MO

ADT/docetaxel HR (95% CI), p ADT/AAP HR (95% CI), p
Nodal +/-bone metastases 0.89 (0.74-1.07), 0.225 0.65 (0.53-0.78), <0.001
Bone only metastases 0.62 (0.46-0.84), 0.002 0.55 (0.41-0.74), <0.001
Prognostic evaluation of nodal burden
Control arm 1.67 (1.13-2.48), 0.011 1.45 (1.07-1.96), 0.016
Research arm 1.58 (0.94-2.67), 0.083 1.42 (1.02-1.98), 0.04

Conclusions

Increased nodal burden is a negative prognostic biomarker and should be considered in prospective risk/volume definitions to aid risk stratification in selected patients. We also demonstrate for the first time a potential differential response between mHSPC pts with nodal +/-bone metastases versus bone-only metastases for ADT + docetaxel but not for ADT + AAP.

Clinical trial identification

NCT00268476.

Editorial acknowledgement

Legal entity responsible for the study

The Christie NHS Foundation Trust and the Medical Research Council Clinical Trials Unit at University College London.

Funding

Surgical Research Fund at The Christie NHS Foundation Trust.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.